

DENNY et al  
Appl. No. 10/529,772  
May 8, 2008

RECEIVED  
CENTRAL FAX CENTER  
MAY 08 2008

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-2 (canceled).

3 (currently amended). ~~The nitroaniline-based unsymmetrical mustard as claimed in claim 1 selected from:~~

~~2-[2-(Aminocarbonyl)(2-chloroethyl)-4,6-dinitroaniline]ethyl methanesulfonate,~~  
~~2-[2-(Aminocarbonyl)(2-bromoethyl)-4,6-dinitroaniline]ethyl methanesulfonate,~~  
~~2-((2-Bromoethyl)-2-[(2-hydroxyethyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate,~~

~~2-((2-Iodoethyl)-2-[(2-hydroxyethyl)amine]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate,~~

~~2-((2-Bromoethyl)-2-[(2-hydroxypropyl)amine]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate,~~

~~2-((2-Bromoethyl)-2-[(2,3-dihydroxypropyl)amine]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate,~~


~~2-((2-Bromoethyl)-2-[(3-(4-morpholinyl)propyl)amine]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate,~~

~~Methyl 3-[(2-((2-chloroethyl)[2-((methylsulfonyloxy)ethyl)amine]-3,5-dinitrobenzoyl)amino)propanoate, and~~

DENNY et al  
Appl. No. 10/529,772  
May 8, 2008

Methyl 3-[(2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-dinitrobenzoyl)amine]propanoate.

4 (currently amended). The A nitroaniline-based unsymmetrical mustard as claimed in claim 1 selected from a compound represented by formula (IIIb)



wherein X, Y, are as defined in claim 4

X represents one of the groups  $\text{NO}_2$ ,  $\text{CN}$ , or  $\text{SO}_2\text{R}^1$ , where  $\text{R}^1$  represents a  $\text{C}_{1-6}$ -alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;

Y represents one of the groups  $\text{OR}^2$ ,  $\text{NHCOR}^2$ ,  $\text{CONHR}^2\text{CO}_2\text{R}^3$ ,

$\text{CONHR}^2$ morpholide,  $\text{CONHR}^2$ ,  $\text{CONR}^2\text{R}^3$ ,  $\text{CONHOR}^2$ ,  $\text{CONHSO}_2\text{R}^2$ ,  $\text{SO}_2\text{NH}_2$ ,

$\text{SO}_2\text{NHR}^2$  or  $\text{SO}_2\text{NR}^2\text{R}^3$  wherein each  $\text{R}^2$  and  $\text{R}^3$  independently represent a H,  $\text{C}_{1-6}$ -alkyl or  $\text{C}_{1-6}$ -alkylene optionally substituted with one or more hydroxy and/or one or more


amino groups; and A and B each independently represent halogen,  $\text{OSO}_2\text{R}^4$ ,  $\text{OSO}_2\text{NH}_2$ ,  $\text{OSO}_2\text{NHR}^4$  or  $\text{OSO}_2\text{NR}^4\text{R}^5$ , wherein each  $\text{R}^4$  and  $\text{R}^5$  independently represent a  $\text{C}_{1-6}$ -alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;

DENNY et al  
Appl. No. 10/529,772  
May 8, 2008

and pharmaceutically acceptable derivatives and salts thereof.

5-7 (canceled).


8 (currently amended). The A method of preparing a nitroaniline-based unsymmetrical mustard represented by formula (IIIb) as claimed in claim 4



wherein X, Y, are as defined in claim 1 for a compound of Formula (IIb)  
X represents one of the groups NO<sub>2</sub>, CN, or SO<sub>2</sub>R<sup>1</sup>, where R<sup>1</sup> represents a C<sub>1-6</sub>-alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;  
Y represents one of the groups OR<sup>2</sup>, NHCOR<sup>2</sup>, CONHR<sup>2</sup>CO<sub>2</sub>R<sup>3</sup>,  
CONHR<sup>2</sup>morpholide, CONHR<sup>2</sup>, CONR<sup>2</sup>R<sup>3</sup>, CONHOR<sup>2</sup>, CONHSO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NH<sub>2</sub>,  
SO<sub>2</sub>NHR<sup>2</sup> or SO<sub>2</sub>NR<sup>2</sup>R<sup>3</sup> wherein each R<sup>2</sup> and R<sup>3</sup> independently represent a H, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkylene optionally substituted with one or more hydroxy and/or one or more amino groups; and A and B each independently represent halogen, OSO<sub>2</sub>R<sup>4</sup>, OSO<sub>2</sub>NH<sub>2</sub>,  
OSO<sub>2</sub>NHR<sup>4</sup> or OSO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, wherein each R<sup>4</sup> and R<sup>5</sup> independently represent a C<sub>1-6</sub>-

DENNY et al  
Appl. No. 10/529,772  
May 8, 2008

alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;  
and pharmaceutically acceptable derivatives and salts thereof;  
the method including comprising the step of reacting a compound of formula



with an amount of LiBr in a polar solvent to give a bromo mesylate of formula (IIIb).

9 (currently amended). The method as claimed in claim 6 8 wherein the polar solvent is selected from the group consisting of acetonitrile, dimethylformamide, ethyl acetate, triethylamine, acetone and mixtures thereof.

10 (currently amended). The method as claimed in claim 6 8 wherein the alkali metal halide is selected from one or more of the following; the group consisting of LiCl, LiBr, NaI and NaBr.

11 (currently amended). A compound of formula  $\text{4b}$  (IIIb) obtained by any one of the methods as claimed in claim 6 8.

DENNY et al  
Appl. No. 10/529,772  
May 8, 2008

12-15 (canceled).

16 (currently amended). A method of cell ablation therapy utilising at least one endogenous nitroreductase enzyme, wherein the method ~~includes~~ comprising the step of administering a compound of Formula  $\text{IIb}$   $\text{IIIb}$  as claimed in claim + 4 in a "therapeutically effective amount" to ablate tumour cells in tissue in a subject, wherein said tissue expresses at least one endogenous nitroreductase enzyme, to activate the compound of formula  $\text{IIb}$   $\text{IIIb}$  into an active metabolite to ablate the tumor cells.

17-18 (canceled).

19 (currently amended). A pharmaceutical composition including comprising a therapeutically effective amount of a compound of formula  $\text{IIb}$   $\text{IIIb}$  as defined in claim + 4 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.

20-21 (canceled).